The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …”

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Biases in larger populations. by Sander W. Keemink (21253563)

“…With amplitude scaling the mean population activity was kept the same by scaling down the response amplitude for larger population (blue curve). …”

Mean PCC vs. perimeter of neighboring RNA genes. by Jiahong Dong (315208)

Expected marginal mean QoL scores for two age cohorts over 2016–2024 in Gauteng, South Africa. by Edmore Marinda (286299)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Expect marginal mean score for individual QoL dimensions for two age cohorts over time in Gauteng South Africa, 2016 - 2024. by Edmore Marinda (286299)

Subjects:

Largest changes in influenza vaccine rates, Pre- vs. Post-COVID-19. by Tyler B. Nofzinger (21560244)

Subjects:

Mean PCC vs. perimeter of neighboring genes in the mouse genome. by Jiahong Dong (315208)

Participant demographics. * P-values were determined using Fisher-Freeman-Halton test when contingency tables are larger than 2 × 2. by Elie Mulhem (22537863)

MRSP Data collected in March 2018. by Alexandra M. Campbell (3284094)

Subjects: